Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.
June 16, 2021
|
2 min read
Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. About 17% of individuals with CF who had Pseudomonas infections last year had multi-drug resistant strains.
Nov. 24, 2020
|
3 min read
CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality
Feb. 22, 2010
|
4 min read